Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04166149 · ClinicalTrials.gov registry record
Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA
A clinical trial, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- 140
- Enrollment target
NCT04166149 is a clinical trial that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 140 participants.
The verdict
NCT04166149 has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
Study Summary
Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function associated with, in the case of kidney transplantation, the presence of interstitial fibrosis (IF) and tubular atrophy (TA) seen in biopsy specimens. Here, we will study the utility of dd-cfDNA to predict rejection in pancreas and pancreas-kidney recipients.
Interventions
- DIAGNOSTIC_TEST dd-cfDNA Blood Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2024-09-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04166149
The ClinicalTrials.gov registry entry for NCT04166149 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dd-cfDNA Blood Test is the first listed.
NCT04166149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04166149 about?
NCT04166149 is a clinical study titled "Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA". Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function associated with, in the case of kidney transplantation, the presence of...
What is the current status of trial NCT04166149?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2019-09-01. Estimated completion is 2024-09-06.
What interventions are being tested in trial NCT04166149?
The interventions under investigation include: dd-cfDNA Blood Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04166149?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.